×
About 1,200 results

ALLMedicine™ Exfoliative Dermatitis Center

Research & Reviews  43 results

Socioeconomic predictors of cost and length of stay for erythroderma: a cross-sectional...
https://doi.org/10.1007/s00403-022-02463-8
Archives of Dermatological Research; Kim YH, Bhandarkar AR et. al.

Nov 12th, 2022 - Erythroderma is an uncommon but serious dermatologic disorder that often requires hospitalization for diagnosis and treatment. However, little is known about predictors influencing cost and patient outcomes. The present study sought to characteriz...

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
https://emedicine.medscape.com/article/1053325-overview

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
http://emedicine.medscape.com/article/1053325-overview

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
https://emedicine.medscape.com/article/1053325-print

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Exfoliative Dermatitis
https://emedicine.medscape.com/article/762236-overview

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

see more →

Drugs  423 results see all →

Clinicaltrials.gov  2 results

sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
https://clinicaltrials.gov/ct2/show/NCT02271724

May 16th, 2016 - Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitab...

Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00748319

Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...

see more →

News  10 results

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors
https://www.onclive.com/view/fda-approves-bevacizumab-adcd-biosimilar-in-six-solid-tumors

Sep 28th, 2022 - The FDA has approved bevacizumab-adcd (Vegzelma), a bevacizumab (Avastin) biosimilar, for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent gliobla...

FDA Approves Third Bevacizumab Biosimilar
https://www.onclive.com/view/fda-approves-third-bevacizumab-biosimilar

Apr 25th, 2022 - The FDA has approved bevacizumab-maly (Almysys), a biosimilar of bevacizumab (Avastin). This regulatory decision represents the third bevacizumab biosimilar to receive the green light in the United States.1,2 The biosimilar was developed by the g...

Survival Not Improved by Adjuvant Bevacizumab in NSCLC
https://www.onclive.com/view/survival-not-improved-by-adjuvant-bevacizumab-in-nsclc

Dec 20th, 2020 - Heather A. Wakelee, MD The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival (OS) in patients with surgically resected early-stage non—small cell lung cancer (NSCLC), according to results of the phase III...

EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis
https://www.onclive.com/view/eu-approves-midostaurin-for-aml-advanced-systemic-mastocytosis

Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...

FDA approves bevacizumab-bvzr for several cancers
https://www.mdedge.com/hematology-oncology/article/203812/gynecologic-cancer/fda-approves-bevacizumab-bvzr-several-cancers
Laura Nikolaides

Jun 28th, 2019 - The Food and Drug Administration has approved bevacizumab-bvzr (Zirabev) – a biosimilar to bevacizumab (Avastin) – for the treatment of five cancers: metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent or metastatic non-.

see more →

Patient Education  2 results see all →